NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients –– Acute unmet need in R/R ...

Get the latest on Curis, Inc.’s Q3 2025 earnings, clinical trial milestones, and investment outlook in rare lymphoma and CLL.

In October 2025, the U.S. Food and Drug Administration (FDA) granted approval to multiple new cancer therapies and supportive ...

NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- BitMart US , a leading crypto exchange, today announced the official launch of its U.S. platform, marking a significant milestone in the company’s expansion ...

TANZANIA internet users utilised only 15 per cent of the available capacity as of September this year. However, the country ...

Good afternoon, ladies and gentlemen, and welcome to the Curis Third Quarter 2025 Business Update Conference Call. [Operator Instructions] This call is being recorded on Thursday, November 6, 2025. I ...

Rigel Pharmaceuticals RIGL is scheduled to report third-quarter 2025 results on Nov. 4, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $61.6 ...

Q1 2026 Earnings Call Transcript November 5, 2025 Operator: Good morning, and welcome to the Jack Henry First Quarter and ...

Plans to develop 135 homes in a Suffolk market town have received 141 objections with many concerned about flooding and an increase in traffic. Framlingham Town Council is also set to object to ...

We led major clinical trials in radiotherapy and imaging which have changed standard clinical practice for cancer treatment.

Developed by Ascentage Pharma, olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent Biologics ...

Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicine, announced today the publication of foundational research demonstrating the power of its proprietary ...